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ABSTRACT The rate of phospholipid vesicle disruption in
specific tissues of the mouse was followed by -ray perturbed
angular correlation (PAC) spectroscopy. In these studies, high
levels of "llIn-nitrilotriacetic acid complex are contained in
unilamellar vesicles consisting of distearoyl phosphatidylcho-
line, cholesterol, and small amounts of other lipids which
modify the surface properties. The PAC technique monitors the
extent of vesicle breakup by measuring a time-integrated per-
turbation factor, <G2do)>. As the vesicles are broken open in
vivo, the released lllln3+ ions quickly bind to macromolecules
and the <G22(o)> value decreases substantially. After admin-
istration of vesicles by various routes (intravenous, intraperi-
toneal, subcutaneous, and oral), the radioactivity and <G2(cx)>
values were determined for several tissues at intervals up to 24
hr. We conclude from these data that (i) the PAC technique in
conjunction with standard oy counting methods provides unique
information on the condition and location of vesicles in specific
tissues, (ii) significant differences in vesicle integrity are found
in various tissues, and (iii) both the means of administration and
the presence of surface charge affect the vesicle stability and
distribution. The carbohydrate analogues of cholesterol affect
vesicle stability but not distribution.
Extensive investigations have been conducted on the structure
of liposomes and their interaction with mammalian cells, as
summarized in several recent reviews (1-5). With the increasing
interest in using liposomes as carriers of pharmacologically
active agents, it becomes necessary to know not only the location
of deposition of administered liposomes, but also the extent to
which they remain intact. Recently, we have shown (6) that
indium-111, encapsulated in liposomes, can be used to obtain
this information. Conventional radioisotope tracer methods can
determine the distribution of "'In, and the overall structural
integrity of liposomes can be monitored in live animals by y-ray
perturbed angular correlation (PAC) studies.
The PAC technique provides information on the tumbling
rate of I''In ions bound to ligands that possess different rota-
tional correlation times (7-9). For example, lllIn3+ chelated
to a small molecule and encapsulated in a liposome exhibits a
fast tumbling rate. However, upon disruption of the bilayer,
the lllIn3+ is released; it rapidly binds to a macromolecule in
the surrounding solution and, consequently, shows a decreased
tumbling rate (6). The chelator, nitrilotriacetic acid (NTA), is
entrapped in the vesicles to minimize binding of indium cations
to phospholipid headgroups. Thus, in a typical experiment in
which NTA-lllIn3+ complex is entrapped in liposomes and
injected into the bloodstream of a mouse, the PAC method can
monitor the relative breakup of liposomes.
In earlier experiments (6), interpretation of data on the
overall rate of vesicle destruction in live animals was limited
by lack of information on structural integrity of vesicles in
specific tissues. By using lipid vesicles that contain high levels
of radioactivity (10), we are now able to obtain this information
quickly. We examine here the effects of certain surface mod-
ifications and routes of administration on the stability of vesicles
in vivo. The surface modifications are produced by incorpo-
rating various charged lipids and carbohydrate analogues of
cholesterol into the lipid bilayer. In addition to intravenous
injection, other means examined for introducing vesicles include
oral, subcutaneous, and intraperitoneal administration.
MATERIALS AND METHODS
Materials. L-a-Dipalmitoyl phosphatidylcholine (Pal2-
PtdCho) (GIBCO, cont. no. C770259), L-a-distearoyl phos-
phatidylcholine (Ste2-PtdCho) (Calbiochem, lot 740123), and
cholesterol (Chol) (Sigma, lot 57C-7190) were used without
further purification. Fucosyl and galactosyl analogues of cho-
lesterol* (FucChol and GalChol, respectively) were gifts from
Merck, Sharp & Dohme. Dicetyl phosphate (Cet2-P) and
stearylamine were purchased from Sigma, the trisodium salt
of NTA from Aldrich, ultrapure InCl3 from Ventron Corp.
(Danvers, MA), and heat-inactivated calf serum from GIBCO.
Cholesteryl [9,10-3H]oleate, specific activity 11 Ci/g (410
GBq/g), was obtained from New England Nuclear. Carrier-free
"'InCl3 was purchased from Medi + Physics (Glendale, CA)
and purified as described (6). The ionophore A23187 was a gift
from Eli Lilly.
Preparation of Vesicles. Unilamellar vesicles with A23187
incorporated into the bilayer were prepared as described (10)
by probe sonication of lipid mixtures in a buffer solution con-
sisting of 1 mM NTA in phosphate-buffered saline (Pi/NaCI),
which is 0.9% NaCI/5 mM sodium phosphate, pH 7.4. Vesicles
of the following compositions were prepared: Pal2-PtdCho:
Chol:A23187 and Ste2-PtdCho:Chol:A23187, both 2:1:0.004
(molar ratio); Ste2-PtdCho:Chol:FucChol:A23187 and Ste2-
PtdCho:Chol:GalChol:A23187, both 2:0.5:0.5:0.004; and Ste2-
PtdCho:Chol:Cet2-P:A23187 and Ste2-PtdCho:Chol:stearyla-
mine:A23187, both 7:2:1:0.01. Because all preparations con-
tained A23187, reference to it will be omitted hereafter from
the designated vesicle compositions. Tritiated cholesteryl oleate
(1 gCi) was included in the mixtures as a marker for the lipid
phase.
After sonication, annealing, and low-speed centrifugation
Abbreviations: PAC, y-ray perturbed angular correlation; NTA, ni-
trilotriacetic acid; Pal2-PtdCho and Ste2-PtdCho, L-a-dipalmitoyl- and
L-a-distearoyl phosphatidylcholine, respectively; Chol, cholesterol;
FucChol and GalChol, fucosyl and galactosyl analogues, respectively,
of cholesterol; Cet2-P, dicetyl phosphate; Pi/NaCI, phosphate-buffered
saline (0.9% NaCI/5 mM sodium phosphate, pH 7.4); <G22(-)>,
time-integrated perturbation factor.
* 6-(1-Thio-l-deoxy-f3-L-fucopyranosyl)-l-(cholest-5-en-3W-yloxy)-
hexane and 6-(1-thio-1-deoxy-f-D-galactopyranosyl)-l-(cholest-
5-en-3f1-yloxy)hexane.
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(10, 11), the NTA external to the liposomes was removed by
passage of the preparation over a Sephadex G-50 column
equilibrated with Pi/NaCl. Determination of the lipid con-
centration in the fractions was based on the tritiated cholesteryl
oleate marker.
For several preparations, the vesicle-size distribution was
determined by electron microscopy after negative staining with
phosphotungstic acid.
Loading Procedure. The use of A23187 to facilitate loading
of vesicles with 1I1In3+ has been described (10). Briefly, after
the Sephadex chromatography, vesicles with A23187 in the
bilayer (typically 5 mg of lipid) were incubated at elevated
temperatures (600C for Pal2-PtdCho, 80'C for Ste2-PtdCho
containing vesicles) for 30 min in Pi/NaCl containing 6.0mM
citrate (pH 7.4)/2.0 X 1O-4mM InCl3 and I11In3 , total volume
0.6 ml. Incubations were terminated by addition of 50 ,l of 10
mM EDTA in Pi/NaCl. Nonloaded lllIn3+ was then removed
by chromatographing the mixture on Sephadex G-50 equili-
brated with Pi/NaCl. Approximately 90% of the added "11In3+
was loaded, with specific activities of up to 300 ,iCi/mg of
lipid.
Studies In Vitro. The effect of serum on the permeability
of vesicles containing lllln3+ was monitored by the PAC
technique (6-9). These studies used a y-ray coincidence spec-
trometer (7) to monitor changes in the rotational correlation
time of the 1llIn ion by measuring the time-integrated per-
turbation factor [<G22(oo)>] of solutions that contain 16 ,uCi
of lllIn3+. Encapsulated lllln3+ (existing at the NTA-lllIn3+
complex) exhibits a high <G22(co)> value due to its rapid
tumbling. Disruption of the lipid bilayer causes release of the
"lIn3 , which rapidly binds to serum proteins (6), resulting in
a decrease in the rotational correlation time of the lllIn3+ as
shown by a decrease in <G22(oo)>. When complete release of
entrapped NTA-lllIn3+ was desired, the vesicles were dis-
rupted by addition of isopropanol. All <G22(o)> values were
measured at room temperature and were corrected to a stan-
dard sample size, 0.20 ml in a 10 X 75 mm glass tube.
Studies In Vivo. Vesicles containing lllIn3+ were adminis-
tered to Swiss-Webster mice (18-22 g) orally or by intravenous
(via tail vein), subeutaneous, or intraperitoneal injection. PAC
studies on live animals required 16 ,uCi of lllIn3+ per mouse;
administration of a minimum of 150,Ci of lllIn3+ per mouse
was necessary for PAC studies on individual tissues. Radiola-
beled vesicles were supplemented with unlabeled vesicles from
the same preparation to adjust the total amount of administered
lipid to the desired level. The volume administered orally was
75 ,l; for injections, the volume was maintained at 0.40 ml/
mouse by addition of Pi/NaCl when necessary.
PAC studies on live animals were conducted on mice con-
fined within the barrel of a modified plastic syringe centered
in the spectrometer, as described elsewhere (6, 12). The syringe
was attached to a clock motor which allowed rotation of the
mouse at 1 rpm to reduce artifacts arising as a result of inho-
mogeneous distribution of §l1In3+ within the animal. No other
correctons of <G22(cx)> values were made to account for the
size or geometry of the mice.
PAC measurements on individual tissues were performed
immediately after the animals were killed. At varying lengths
of time after administration of IIIIn3+, the mice were killed by
cervical dislocation followed immediately by decapitation.
Organs and tissues were washed with 0.9% NaCI, blotted, and
weighed. PAC measurements of all tissues were completed
within 1 hr. No change in <G22(o)> value was observed for
samples remeasured within this time period. The distribution
of injected radioactivity was determined by assaying the tissue
samples in a well-type y-ray spectrometer. Distributions are
reported on a per organ basis. Blood was assumed to comprise
7.3% of the total weight of the animal.
RESULTS
Establishment of Standard Conditions. Measurement of
<G22(oo)> values for lllIn3+ provides an estimate of the rota-
tional correlation time of the molecule to which the "'1In ion
is bound (9). Values of <G22(co)> for lllIn3+ in various envi-
ronments are shown in Table 1. NTA-lllIn+ complex that is
not encapsulated in vesicles interacts rapidly with serum and
exhibits an accompanying decrease in <G22(co)> (6, 10). The
slightly reduced values for the complex entrapped in vesicles
presumably result from limited interaction of the lllIn3+ with
the phospholipid headgroups or from some restriction of the
rotational mobility of the complex when it is confined within
the aqueous compartment of a vesicle. Electron microscopy
indicates that the Ste2-PtdCho:Chol vesicles are slightly larger
than the Pal2-PtdCho:Chol vesicles (mean diameters of 720 i
40 A and 650 + 20 A, respectively). No change in the mean
diameter of the vesicle preparations could be detected when
the carbohydrate analogues of cholesterol were substituted for
part of the cholesterol in the bilayer.
The data in Table 1 show that both the Pal2-PtdCho and
Ste2-PtdCho vesicle systems maintain their structural stability
in the presence of serum at room temperature. However, at
370C serum has a very marked adverse effect on the stability
of Pal2-PtdCho:Chol vesicles. In order to examine the role of
vesicle bilayer and surface constituents on vesicle stability in
vivo, it is imperative to select as a standard lipid system one
which exhibits substantial stability in vitro. The Ste2-PtdCho:
Chol appears to satisfy this requirement, and for purposes of
comparison it is used as the standard system throughout this
investigation.
Preliminary experiments indicated substantial variability
in the amount of radioactivity that was rapidly removed from
the blood by the liver after administration of vesicles containing
lllIn3+. For example, the amount of lllIn3+ recovered in the
liver 3 hr after intravenous injection of Ste2-PtdCho:Chol ves-
icles ranged between 18 and 80% of the injected dose. This
variability is dependent on the amount of administered lipid
(Fig. 1). To circumvent this dose-dependent and potentially
unselective uptake of vesicles by the liver, administered dosages
were standardized at 1.0 mg of lipid per mouse. Use of this
amount, which is clearly sufficient to saturate the liver for the
Ste2-PtdCho:Chol system and presumably for the other systems
Table 1. <G22(-)> values for ll"In3+ in vesicles and
various environments*
Without With With serum, With serum
serum serum 30 min, 37°C + isopropanol
NTA-"11In3+ 0.70 0.19 0.19 0.18
Pal2-PtdCho:Chol 0.59 0.54 0.43t 0.17
Ste2-PtdCho:Chol 0.63 0.62 0.62t 0.20
Ste2-PtdCho:Chol:
GalChol 0.60 0.60 0.61 0.24
Ste2-PtdCho:Chol:
FucChol 0.62 0.61 0.60 0.24
Ste2-PtdCho:Chol:
Cet2-P 0.61 0.60 0.59 0.23
Ste2-PtdCho:Chol:
SA§ 0.62 0.62 0.55 0.21
* All samples in P/NaCl prior to addition of 1 vol of heat-inactivated
calf serum. Error in all measurements is ±0.02.
t 0.28 after 12 hr at 37°C.
I Value unchanged after 48 hr at 371C.
§ SA, stearylamine.
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FIG. 1. Saturation of liver by lipid vesicles. Mice were killed 3 hr
after receiving varying amounts of Ste2-PtdCho:Chol vesicles by in-
travenous injection. Each 0.40-ml injection contained ~3.0 ,uCi of
encapsulated lllIn3+. The fractional activity in blood is defined as
(total '11In3+ in blood)/[(total 111In3+ in blood) + (total "1In3+ in
liver)l.
investigated, should also eliminate differences arising from
minor variations in animal size.
Intravenous Administration. The tissue distribution of
lI1n3+ was determined at various time intervals after intra-
venous administration of vesicles containing entrapped IllIn3+
(Fig. 2). The blood~and liver contained most of the activity at
short time points for all vesicle compositions examined. For
example, with the Ste2-PtdCho:Chol system 10 min after ad-
ministration, 90 ± 14% and 11 ± 3% of the recovered activity
were found in the blood and liver, respectively (average of four
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FIG. 2. Tissue distribution of recovered "llIn3+ after intravenous
injection of NTA-1llIn3+ or vesicles containing entrapped NTA-
11In3+. (A and B) Distributions for mice killed after 3 and 24 hr, re-
spectively. C, Ste2-PtdCho:Chol vesicles; G, Ste2PtdCho:Chol:Gal-
Chol; F, Ste2-PtdCho:Chol:FucChol; D, Ste2-PtdCho:Chol:Cet2-P;
S, Ste2-PtdCho:Chol:stearylamine; and N, free NTA-111In3+. Each
bar represents the mean of two to six mice. Error bars for C, G, and
F are ±SEM of six, four, and four mice, respectively. Because no
corrections were made for the blood content of various tissues, the
totals can be greater than 100% when significant radioactivity is in
the blood. Each 0.40-ml injection contained 1.0 mg of lipid (no lipid
in N) and >15 1ACi of 111In3 .
mice). For all distributions reported, no corrections were made
for the blood content of the various tissues, which accounts for
the greater than 100% activity noted at short times. At long time
points, e.g., 24 hr (Fig. 2), the liver was the major site of depo-
sition of lllIn3+ for all vesicle systems. However, negatively
charged vesicles (Ste2-PtdCho:Chol:Cet2-P) showed signifi-
cantly less, and positively charged vesicles (Ste2-PtdCho:
Chol:stearylamine) significantly more, IllIn3+ deposition in
the liver than either the standard system or the vesicles con-
taining the carbohydrate analogues. At all time points exam-
ined, the distribution of 111In3+ after administration of free
NTA-IllIn3+ complex did not resemble that from the vesicle
systems. Recoveries for all systems were usually greater than
90% of the injected dose.
The overall stability of the vesicle preparations in live animals
was examined by the PAC technique (Fig. 3). During the first
30 min after intravenous injection, only the negatively charged
vesicles showed substantially reduced stability in vivo. At longer
times it is clear that both charged vesicle systems, and to a lesser
extent both carbohydrate analogue systems, show greater loss
of structural integrity than the standard system.
The tissue distribution data at 3 hr (Fig. 2) shows similar
profiles for the Ste2-PtdCho:Chol and Ste2-PtdCho:Chol:Fuc-
Chol systems, with at most only a marginally lower lllIn3+ level
in the liver for the Ste2-PtdCho:Chol:FucChol system. Since the
liver is presumably a site for destruction of vesicles, the distri-
bution data do not explain the lower overall stability in vivo for
the Ste2-PtdCho:Chol:FucChol system (Fig. 3). However, ex-
amination of the <G22(co)> values at 3 hr for individual tissues
(Table 2) reveals that for several tissues (e.g., kidney, chest tis-
sue, and skin) the extent of vesicle destruction is much greater
with the Ste2-PtdCho:Chol:FucChol system. With the charged
vesicle systems the kidney and skin have even lower proportions
of intact vesicles than observed with the Ste2-PtdCho:Chol:
FucChol system.
The blood content of the individual tissues will influence the
observed <G22(cx)> value. This is a significant factor for highly
vascular tissue such as the liver and at early time points when
the "'.In3+ content of the blood is high. Within the limits of
detection, all the "'IIn3+ in the blood in the standard vesicle
system remains encapsulated even at 24 hr after injection (Table
2). In contrast, the <G22(co)> data for the Ste2-PtdCho:Chol:
Cet2-P system suggest that some vesicle destruction occurs in
the circulation. This destruction is seen in the lower <G22(o)>
values observed initially with the whole mice (Fig. 3).
Other Routes of Administration. The overall distribution
and stability of the vesicle systems when administered by in-
traperitoneal injection approximates that observed after in-
travenous administration. However, considerable variability
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FIG. 3. Stability of vesicle preparations in live mice after intra-
venous administration. A, Ste2-PtdCho:Chol vesicles; 0, Ste2-
PtdCho:Chol:FucChol; 0, Ste2-PtdCho:Chol:GalChol; 0, Ste?-
PtdCho:Chol:stearylamine; *, Ste2-PtdCho:Chol:Cet2-P. Each set
of points is the average of two mice. Each 0.40-ml injection contained
1.0mg of lipid with 16 gCi of entrapped l11In3 .
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Table 2. <G22(qo)> values of tissue after intravenous injection of vesicles containing lllIn3+ *
\ ~~~~~~~~~~~~~~~~~~~~~~Ste2-PtdCho:Ste2-PtdCho:
\ ~~~~~~Ste2-PtdCho:ChoI Ste2-PtdCho:Chol:FucChol Chol:SAt Chol:Cet2--P
Tisu \ hr 3 24 3 12 24 12 12
Blood 0.62 0.61 0.61 0.57 0.60 0.52
Liver 0.43 0.26 0.44 0.24 0.21 0.23 0.29
Spleen 0.54 0.24 1 t 0.25 0.17 0.28
Kidney 0.48 0.24 0.35 0.42 0.22 0.31 0.28
Sm. Int. 0.42 0.33 0.48 0.31 0.23 0.26 0.32
Lg. Int. 0.24 0.25 0.29 0.22 0.24
Abd. Tiss. 0.49 0.45 0.37 0.29 0.25 0.28
Chest Tiss. 0.51 0.29 0.43 0.34 0.26 0.34 0.34
Extremities t t 0.41 0.26 0.22
Skull 0.49 0.25 0.42 0.32 0.19
Skin 0.50 0.28 0.37 0.35 0.30 0.27 0.27
* Variability between duplicate samples is <0.03.
t SA, stearylamine.
Not measured.
in the rate and the extent of removal of vesicles from the in-
jection site is observed with intraperitoneal administration.
After subcutaneous injection of radiolabeled vesicles, the
lll1n3+ is recovered predominantly in the skin near the site of
injection even 24 hr after administration (Table 3). A small
amount of radioactivity is found in the chest tissue that is ad-
jacent to the injection site. The <G22(9)> values on live mice
(Fig. 4) clearly show that the vesicles remain intact for nearly
10 hr and then are rapidly degraded. For example, the
<G22(cD)> value for skin 12 hr after subcutaneous adminis-
tration of Ste2-PtdCho:Chol:GalChol vesicles was 0.40. Varia-
tion in the amount of vesicles administered subcutaneously (e.g.,
0.1-1.5 mg of lipid and 0. 1-0.42 ml total volume) did not cause
any substantial difference in the vesicle lifetime.
In contrast to the subcutaneous results, orally administered
unilamellar vesicles are destroyed within the time necessary
to complete a single PAC measurement (Fig. 4). The tissue
distribution of recovered lllIn+ indicates that vesicles are not
absorbed into the circulation from the gastrointestinal tract
(compare low percentage in blood and liver). The <G22(oo).
Table 3. Tissue distribution of recovered ll'In3+
\ ~~~Subcutaneous
\ ~~~~injection Oral administration
\ S~~te2-PtdCho: Ste2-PtdCho: Ste2-PtdCho:
\ Chol:GalChol Chol Chol:GalChol
Tissue\, hr -12 24 1 3
Blood 1.0 0.3 0.04 0.05
Lung 0.1 0.05 0.02 t
Liver 1.1 2.2 0.02 0.01
Spleen 0.09 0.08 t t
Kidney 0.4 0.4 0.02 0.01
Stomach 0.06 0.1 4.0 29
SmallInt. 0.7 1.9 73 48
Large Int. 0.6 2.2 20 17
Abd. Tiss. 3.9 5.7 0.4 0.2
Chest
Tiss. 22 14 0.1 0.7
Extremi-
ties 0.6 0.6 0.7 0.4
Skull 0.5 0.4 0.9 2.0
Skin 70 72 0.9 2.1
* Expressed as percent of total recovered radioactivity. For all sys-
tems, heart '0.04 and brain S0.01.
t Below limit of detection.
values for times corresponding to those in Table 3 show that the
vesicles have broken open and the lllIn3+ has bound to the
contents of the digestive system. For example, at 1 hr for the
Ste2-PtdCho:Chol system, the <G22(oo)> values for the small
and large intestine were 0.27 and 0.23, respectively. At 3 hr with
the Ste2-PtdCho:Chol:GalChol system, the <G22(o)> values
for the stomach and small intestine were 0.27 and 0.25, re-
spectively. The rate of vesicle destruction is not dependent on
the amount of lipid administered orally over the range exam-
ined (0.1-1 mg).- However, the rate of passage of radioactivity
through the gastrointestinal tract is dependent on the feeding
habits of the individual animals.
DISCUSSION
Entrapment of therapeutic materials in lipid vesicles can po-
tentially afford protection for the material and direct it to de-
sired locations. However, attempts to determine the fate of
administered liposomes by classical radioisotope tracer methods
have been complicated by the difficulty in distinguishing en-
trapped radioactivity from that released from the liposomes.
We have recently shown (6) that PAC techniques can be used
to establish the overall structural integrity of lipid vesicles in
live animals by monitoring the molecular motion of lllIn3+
originally trapped in the aqueous phase of the liposomes. Using
vesicles containing high specific activities of '11In3+ (10), we
are now able to determine the extent of vesicle destruction in
individual organs and tissues, and, therefore, can more ade-
quately interpret the overall rates of vesicle destruction ob-
served in live'animals.
Factors affecting the fate of lipid vesicles in vivo include the
amount, composition, and route of administration of vesicles.
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FIG. 4. Vesicle stability in live mice after (A) oral or (B) subcu-
taneous administration. *, Ste2-PtdCho:Chol vesicles; 0, Ste2-
PtdCho:Chol:GalChol. The data sets are the average of two mice.
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Recently, Blumenthal et al. (13) described the presence of
saturable sites on human lymphocytes for the transfer of lipo..
somal contents into the cell interior. The presence of similar
unselective saturable sites in the liver is suggested by recent
work of Caride et al. (14) and Gregoriadis et al. (15). They
found that administration of large quantities of nonradioactive
liposomes (7 and 25 mg of lipid per mouse, respectively) re-
sulted in a reduction in uptake of radiolabeled liposomes by the
liver. By examining hepatic uptake as a function of adminis-
tered dose, we show that <0.5 mg of our lipid vesicles is suffi-
cient to saturate the liver of a mouse. Use of larger amounts of
lipid should therefore overcome this rapid and unselective
uptake by the liver and allow time for recognition of vesicle
determinants by other tissues.
The possibility that surface carbohydrate groups may serve
as determinants for recognition of liposomes by particular
tissues is raised by the work of Lunney and Ashwell (16) which
describes a specific hepatic receptor capable of recognizing and
binding galactose-terminated glycoproteins. The results pre-
sented here show that the presence of either fucose or galactose
on the surface of Ste2-PtdCho:Chol vesicles causes no statisti-
cally significant alteration in the tissue distribution of the ves-
icles. These findings do not necessarily indicate the absence of
appropriate receptors for the modified vesicles. Factors af-
fecting conformation or accessibility may be important in
recognition, as indicated in recent work by Bussian and Wriston(17) on the influence of cerebrosides on the interaction of li-
posomes with the HeLa cells. They incorporated synthetic
cerebrosides containing glucose, galatcose, or lactose as the sugar
component into multilamellar liposomes. The presence of ga-
lactose cerebroside caused a modest increase in uptake of li-
posomes by HeLa cells. However, they found that lactocere-
broside had about a 2-fold greater effect on incorporation than
galactocerebroside, suggesting that the glucosyl moiety of the
disaccharide allowed better interaction of the terminal galactose
with the putative cell-surface receptor.
Results presented here clearly indicate that the charge of the
vesicles may be of great importance in achieving targeting of
intact liposomes to desired tissues. The positively charged
Ste2-PtdCho:Chol:stearylamine vesicles were accumulated in
the liver to a significantly higher level than any other system
examined. The cause of this apparent targeting is not known,
but it may arise from a change in the extent of interaction of
vesicles with particular cell types or a change in the mechanism
of liposome-cell interaction (1, 18). The decreased stability of
charged vesicles observed for several tissues may also indicate
a change in the mechanism of vesicle-cell interaction (e.g., from
stable adsorption to endocytosis). The PAC measurements on
individual tissues show that vesicle stability is also a function
of tissue type. For example, vesicles in the blood can remain
completely intact while those in other tissues, such as liver and
intestine, are extensively disrupted.
The role of the route of administration on the fate of vesicles
is most dramatic. Our findings with subcutaneous adminis-
tration agree with a previous report (19) indicating that most
of the vesicles remain at the site of injection. The PAC mea-
surements indicate that the localized vesicles do remain intact
for an extended period of time (_10 hr). In contrast, we find
that within 5 min after oral administration, the "1In3+ en-
trapped in our vesicle systems becomes exposed to the contents
of the stomach. Although a likely cause of this exposure is that
the vesicles are disrupted, we cannot exclude the possibility that
the release of indium results from an increase in the perme-
ability of the bilayer in the gastrointestinal tract. No significant
absorption of 1llIn3+ from the gastrointestinal tract into the
circulation was observed. However, in experiments on liposo-
mally entrapped insulin, Patel and Ryman (20) conclude that
in the stomach most of the insulin is still entrapped within li-
posomes 15 min after oral administration. This apparent dis-
crepancy may arise from use of liposomes differing in com-
position and lamellar structure or from the method of analysis.
Particularly, the chromatography used by Patel and Ryman
may fail to distinguish between liposomally associated and
entrapped insulin. This is a salient point in view of comments
by Gregoriadis et al. (21) that insulin seems to interact with
disrupted phosphatidylinositol liposomes, which may facilitate
transport of insulin into the blood.
The techniques developed for examination of liposome sta-
bility by PAC techniques make possible the systematic exam-
ination of vesicle systems at both the tissue and live animal
levels. It is anticipated that this type of information will be of
considerable importance in developing optimal conditions for
uptake and targeting of liposomally entrapped therapeutic
agents.
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